Details

Autor(en) / Beteiligte

• Liu, Yanjun
• Qin, Liying
• Tan, Guoying
• Guo, Yanan
• Fan, Yifan
• Song, Nan
• Zhou, Ping
• Yan, Chun‐Hua
• Tang, Yu

Titel

Titanium‐Based Superlattice with Fe(III)‐Regulable Bandgap and Performance for Optimal and Synergistic Sonodynamic–Chemotherapy Guided by Magnetic Resonance Imaging

Ist Teil von

• Angewandte Chemie International Edition, 2023-11, Vol.62 (47), p.e202313165-n/a

Auflage

International ed. in English

Ort / Verlag

Weinheim: Wiley Subscription Services, Inc

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Superlattices have considerable potential as sonosensitizers for cancer therapy because of their flexible and tunable band gaps, although they have not yet been reported. In this study, a Ti‐based organic–inorganic superlattice with good electron–hole separation was synthesized, which consisted of orderly layered superlattices of 2,2′‐bipyridine‐5,5′‐dicarboxylic acid (BPDC) and Ti−O layers. In addition, the superlattice was coordinated with Fe(III) and encapsulated doxorubicin (DOX) to prepare Ti‐BPDC@Fe@DOX@PEG (TFDP) after biocompatibility modification. TFDP can realize the simultaneous generation of reactive oxygen species and release of DOX under ultrasound irradiation. Moreover, adjusting the Fe(III) content can effectively modulate the band gap of the superlattice and increase the efficiency of sonodynamic therapy (SDT). The mechanisms underlying this modulation were explored. TFDP with Fe(III) can also be used as a contrast agent for magnetic resonance imaging (MRI). Both in vitro and in vivo experiments demonstrated the ability of TFDP to precisely treat cancer using MRI‐guided SDT/chemotherapy. This study expands the applications of superlattices as sonosensitizers with flexible and tailored modifications and indicates that superlattices are promising for precise and customized treatments. In this study, we developed a sonosensitizer by using superlattices for sonodynamic therapy (SDT) with sonication‐triggered drug release. Introducing Fe(III) through coordinated interactions and changing the Fe(III) content can efficiently enhance and modulate the band gap and improve the outcomes of SDT. Benefiting from the use of Fe(III) as a contrast agent, magnetic resonance imaging‐guided and synergistic therapy can be realized.